VALENCIA, Spain, Feb. 28, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced that the U.S. Food and Drug Administration (FDA) cleared the Company to initiate the Phase I-IIa ArthemiR™ study of ATX-01 for the treatment of Myotonic Dystrophy Type 1 (DM1).
VALENCIA, Spain, Oct. 24, 2023 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today the presentation of posters and oral talks at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place October 22-25, 2023, in Barcelona, Spain, and Tides Europe 2023, taking place October 30-November 1, 2023, in Amsterdam, NL.
VALENCIA, Spain, Sept. 28, 2023 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today that it will present at Chardan's 7th Annual Genetic Medicines Conference. Frédéric Legros, Chairman and CEO, will deliver a presentation on Tuesday, October 3, 2023 at 8:30am ET. Dr. Legros will also participate in one-on-one meetings with potential investors during the conference.
VALENCIA, Spain, May 9, 2023 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today a presentation at the TIDES USA Oligonucleotide & Peptide Therapeutics annual meeting being held May 7-10, 2023, in San Diego, CA.
ARTHEx Biotech has raised €42 million (about $46 million) in Series B funds to bankroll an early-stage study of a drug candidate in myotonic dystrophy type 1, or DM1.
VALENCIA, Spain, Dec. 14, 2022 /PRNewswire/ -- Arthex Biotech S.A., a pre-clinical-stage biotechnology company pioneering innovative microRNA modulating approaches to diseases with high unmet medical needs, today announced that it has met key regulatory milestones in its program to develop ATX-01 in Myotonic Dystrophy Type 1 (DM1), opening a clear path forward to filing an Investigational New Drug (IND) application in the USA and a Clinical Trial Application (CTA) in Europe.
VALENCIA, Spain, Nov. 28, 2022 /PRNewswire/ -- Arthex Biotech S.A., a pre-clinical stage biotechnology company pioneering innovative microRNA modulating approaches to diseases with high unmet medical needs, today announced that Frédéric Legros, PhD, has joined the Company's Board of Directors as Executive Chairman.